Verona Pharma PLC PDMR Dealing (4787A)

TIDMVRP

RNS Number : 4787A

Verona Pharma PLC

29 May 2019

Verona Pharma plc

PDMR Dealing

May 29, 2019, LONDON - Verona Pharma plc (AIM:VRP) (Nasdaq:VRNA) ("Verona Pharma"), a biopharmaceutical company focused on respiratory diseases, announces that, on May 28, 2019, Kayt Morgan, spouse of Mr. Piers Morgan, CFO of the Company, purchased 33,802 ordinary shares of 5 pence each in the Company (the "Ordinary Shares") at a price of 59 pence per Ordinary Share and a total purchase price of GBP19,954.18. Following the acquisition, Mr. Morgan will have a beneficial interest in the Company of 147,009 Ordinary Shares, representing 0.14% of the Company's issued share capital.

This purchase brings the total purchases by Mr. and Mrs. Morgan during the past few months to over GBP52,000 and follows the purchases made by the Company's Chairman, Dr. David Ebsworth, in March totaling approximately GBP50,000.

The notification set out below is provided in accordance with the requirements of the EU Market Abuse Regulation.

 
 1     Details of the person discharging managerial responsibilities/person 
        closely associated 
 a)    Name                                  Kayt Morgan 
      ------------------------------------  --------------------------------- 
 2     Reason for the notification 
      ----------------------------------------------------------------------- 
                                             Spouse (PCA) of Piers Morgan, 
  a)    Position/status                       Chief Financial Officer 
      ------------------------------------  --------------------------------- 
 b)    Initial notification/Amendment        Initial notification 
      ------------------------------------  --------------------------------- 
 3     Details of the issuer, emission allowance market participant, 
        auction platform, auctioneer or auction monitor 
      ----------------------------------------------------------------------- 
 a)    Name                                  Verona Pharma plc 
      ------------------------------------  --------------------------------- 
 b)    LEI                                   213800EVI6O6J3TIAL06 
      ------------------------------------  --------------------------------- 
 
 
 4    Details of the transaction(s): section to be repeated for (i) 
       each type of instrument; (ii) each type of transaction; (iii) 
       each date; and (iv) each place where transactions have been 
       conducted 
 a)   Description of the financial instrument, type of instrument   Ordinary Shares of 5 pence each 
       Identification code                                           GB00BYW2KH80 
     ------------------------------------------------------------  ------------------------------------ 
 b)   Nature of the transaction                                     Purchase of Ordinary Shares 
     ------------------------------------------------------------  ------------------------------------ 
 c)   Price(s) and volume(s)                                            Price(s)          Volume(s) 
                                                                      59 pence per      33,802 Ordinary 
                                                                       Ordinary Share    Shares 
                                                                                       ---------------- 
     ------------------------------------------------------------  ------------------------------------ 
 d)   Aggregated information                                        N/A 
       - Aggregated volume 
       - Price 
     ------------------------------------------------------------  ------------------------------------ 
 e)   Date of the transaction                                       28 May 2019 
     ------------------------------------------------------------  ------------------------------------ 
 f)   Place of the transaction                                      London Stock Exchange, AIM 
     ------------------------------------------------------------  ------------------------------------ 
 

For further information, please contact:

 
Verona Pharma plc                                Tel: [phone] 
Jan-Anders Karlsson, Chief Executive Officer     [e-mail] 
 Victoria Stewart, Director of Communications 
 
N+1 Singer                                       Tel: [phone] 
 (Nominated Adviser and UK Broker) 
Aubrey Powell /Jen Boorer /Iqra Amin (Corporate 
 Finance) 
 Mia Gardner (Corporate Broking) 
 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

END

DSHALMMTMBMTBAL

(END) Dow Jones Newswires

May 29, 2019 06:07 ET (10:07 GMT)